Elanco Animal Health (NYSE:ELAN) Hits New 12-Month High - Here's Why

Key Points

• Elanco Animal Health's stock reached a new 12-month high of $18.91 during mid-day trading, indicating strong investor interest and trading volume.
• Analysts have raised their price targets for the stock, with UBS Group setting a new target of $19.00 and Piper Sandler adjusting theirs to $18.00, reflecting positive sentiment among equity research analysts.
• Elanco reported earnings of $0.26 per share in its latest quarter, exceeding analyst expectations and showing a revenue increase of 4.8% year-over-year, which solidifies its financial position.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.91 and last traded at $18.74, with a volume of 1371449 shares changing hands. The stock had previously closed at $18.43.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ELAN shares. UBS Group boosted their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Piper Sandler upped their price target on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, August 11th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Finally, William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Stock Performance

The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average of $15.95 and a 200 day moving average of $12.94. The company has a market capitalization of $9.32 billion, a price-to-earnings ratio of 21.76, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period in the prior year, the firm earned $0.30 earnings per share. Elanco Animal Health's revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ELAN. Allworth Financial LP grew its stake in Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the period. CoreCap Advisors LLC bought a new position in shares of Elanco Animal Health during the 4th quarter worth $29,000. NBC Securities Inc. bought a new position in shares of Elanco Animal Health during the 1st quarter worth $40,000. Parallel Advisors LLC lifted its holdings in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc lifted its holdings in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after purchasing an additional 1,740 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.